Accelerating the Evolution of Immune-Related Enterocolitis Management

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2023 Apr 11

PMID 37040601

Authors

David M Faleck

Michael Dougan

Monique Tello

Joseph E Grossman

Alan C Moss

Michael A Postow

Affiliations

Soon will be listed here.

Citing Articles

Preoperative pembrolizumab‑induced hemophagocytic lymphohistiocytosis in a patient with breast cancer: A case report.

Kawamura Y, Shimomura A, Taniyama T, Hirai H, Hashimoto K, Honda Y Oncol Lett. 2025; 29(3):136.

PMID: 39839606 PMC: 11747951. DOI: 10.3892/ol.2025.14882.

References

Lichtenstein G, Feagan B, Cohen R, Salzberg B, Diamond R, Price S . Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012; 107(9):1409-22. PMC: 3438468. DOI: 10.1038/ajg.2012.218. View

Abu-Sbeih H, Ali F, Wang X, Mallepally N, Chen E, Altan M . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019; 7(1):93. PMC: 6444537. DOI: 10.1186/s40425-019-0577-1. View

Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R . Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. Gastroenterology. 2021; 162(2):482-494. DOI: 10.1053/j.gastro.2021.10.037. View

Berg D, Colombel J, Ungaro R . The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019; 25(12):1896-1905. PMC: 7185690. DOI: 10.1093/ibd/izz059. View

Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster C . Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4):457-65. DOI: 10.1517/14740338.2016.1140743. View

Fiske J, Conley T, Sebastian S, Subramanian S . Infliximab in acute severe colitis: getting the right dose. Frontline Gastroenterol. 2020; 11(6):427-429. PMC: 7569519. DOI: 10.1136/flgastro-2020-101407. View

Johnson D, Zobniw C, Trinh V, Ma J, Bassett Jr R, Abdel-Wahab N . Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018; 6(1):103. PMC: 6180568. DOI: 10.1186/s40425-018-0412-0. View

Bai X, Hu J, Betof Warner A, Quach H, Cann C, Zhang M . Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021; 27(21):5993-6000. PMC: 9401488. DOI: 10.1158/1078-0432.CCR-21-1283. View

Luo J, Beattie J, Fuentes P, Rizvi H, Egger J, Kern J . Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021; 16(10):1759-1764. PMC: 8464489. DOI: 10.1016/j.jtho.2021.06.024. View

10.

Wolchok J, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L . Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2009; 11(2):155-64. DOI: 10.1016/S1470-2045(09)70334-1. View

11.

Maher V, Fernandes L, Weinstock C, Tang S, Agarwal S, Brave M . Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol. 2019; 37(30):2730-2737. DOI: 10.1200/JCO.19.00318. View

12.

DHaens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H . Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371(9613):660-667. DOI: 10.1016/S0140-6736(08)60304-9. View

13.

Luoma A, Suo S, Williams H, Sharova T, Sullivan K, Manos M . Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 2020; 182(3):655-671.e22. PMC: 7415717. DOI: 10.1016/j.cell.2020.06.001. View

14.

Weber J, Postow M . TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?. Clin Cancer Res. 2020; 26(9):2085-2086. DOI: 10.1158/1078-0432.CCR-20-0387. View

15.

Dougan M, Luoma A, Dougan S, Wucherpfennig K . Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021; 184(6):1575-1588. PMC: 7979511. DOI: 10.1016/j.cell.2021.02.011. View

16.

Waljee A, Rogers M, Lin P, Singal A, Stein J, Marks R . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017; 357:j1415. PMC: 6284230. DOI: 10.1136/bmj.j1415. View

17.

OConnor A, Marples M, Mulatero C, Hamlin J, Ford A . Ipilimumab-induced colitis: experience from a tertiary referral center. Therap Adv Gastroenterol. 2016; 9(4):457-62. PMC: 4913344. DOI: 10.1177/1756283X16646709. View

18.

Collins M, Soularue E, Marthey L, Carbonnel F . Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol. 2020; 18(6):1393-1403.e1. DOI: 10.1016/j.cgh.2020.01.033. View

19.

Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali F, Qiao W . Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018; 6(1):37. PMC: 5946546. DOI: 10.1186/s40425-018-0346-6. View

20.

Horvat T, Adel N, Dang T, Momtaz P, Postow M, Callahan M . Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015; 33(28):3193-8. PMC: 5087335. DOI: 10.1200/JCO.2015.60.8448. View